• 1
    Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Int Med 1966; 64 (2): 32840.
  • 2
    Fainstein V, Rodriguez V, Turck M et al Patterns of oropharyngeal ans fecal flora in patients with adult leukemia. J Infect Dis 1981; 144: 826.
  • 3
    Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer; emphasis on Gram-positive and resistant bacteria. Clin Infect Dis 1999; 29: 4904.
  • 4
    Kerr KG. The prophylaxis of bacterial infections in neutropenic patients. J Antimicrobial Chemotherapy 1999; 44: 58791.
  • 5
    Schimpff SC, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971; 284: 10615.
  • 6
    De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP. Ceftazidime compared with piperacillin and trobramycin for the empirical treatment of fever in neutropenic patients with cancer – a multicenter randomized trial. Ann Intern Med 1994; 120: 83444.
  • 7
    De Pauw BE, Raemaekers JM, Schattenberg A, Donnelly JP. Empirical and subsequent use of antibacterial agents in the febrile neutropenic patient. J Intern Med 1997; 242 (Suppl. 740): 6977.
  • 8
    Ramphal R, Bolger M, Oblon DJ. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime – a randomized prospective study. Antimicrob Agents Chemother 1992; 36: 44552.
  • 9
    Novakova IR, Donnelly JP, De Pauw BE. Ceftazidime as monotherapy or combined with teicoplanin for initial empirical treatment of presumed bacteremia in febrile granulocytopenic patients. Antimicrob Agents Chemother 1991; 35: 6728.
  • 10
    The EORTC International Antimicrobial Therapy Cooperative Group and National Cancer Institute of Canada. Vancomycin added to empirical combination therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991; 163: 9518.
  • 11
    Kruger W, Russman B, Kroger N et al Early infections in patients undergoing bone marrow or blood stem cell transplantation – a 7 year single centre investigation of 409 cases. Bone Marrow Transplant 1999; 23: 58997.
  • 12
    Erjavec Z, De Vries-Hospers HG, Laseur M, Halie R, Daenen S. A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. J Antimicrobial Chemotherapy 2000; 45: 8439.
  • 13
    Dompeling E, Donnelly JP, Deresinski SC et al Early identification of neutropenic patients at risk of Gram-positive bacteraemia and the impact of empirical administration of vancomycin. Eur J Cancer 1996; 32A (8): 13329.
  • 14
    Hoiby N, Jarlov JO, Kemp M et al Excretion ciprofloxacin in sweat and multiresistant staphylococcus epidermidis. Lancet 1997; 349: 1679.
  • 15
    Hoiby N, Pers C, Johansen HK, Hansen H. Excretion of beta-lactam antibiotics in sweat – a neglected mechanism for development of antibiotic resistance? Antimicrob Agents Chemother 2000; 44: 28557.
  • 16
    Carratala J, Alcaide F, Fernandez-Sevilla A et al Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer. Clin Infect Dis 1995; 20: 116973.
  • 17
    Bilgrami S, Feingold JM, Dorsky D et al Streptococcus viridans bacteremia following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1998; 21: 5915.
  • 18
    Donnelly JP, Muus P, Schattenberg A et al A scheme for daily monitoring of oral mucositis in allogeneic BMT recipients. Bone Marrow Transplant 1992; 9 (6): 40913.
  • 19
    Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 1998; 82 (11): 227581.
  • 20
    Donnelly JP, Dompeling EC, Meis JF, De Pauw BE. Bacteremia due to oral viridans streptococci in neutropenic patients with cancer: cytostatics are a more important risk factor than antibacterial prophylaxis. Clin Infect Dis 1995; 20 (2): 46970.
  • 21
    Engelhard D, Elishoov H, Or R et al Cytosine arabinoside as a major risk factor for streptococcus viridans septicemia following bone marrow transplantation: a 5 year prospective study. Bone Marrow Transplant 1995; 16: 56570.
  • 22
    Bochud P-Y, Eggiman Ph, Calandra Th et al Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 1994; 18: 2531.
  • 23
    Muus P, Donnelly P, Schattenberg A et al Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent. Semin Oncol 1993; 20 (6 Suppl. 8): 4752.
  • 24
    Meurman JH, Pyrhonen S, Teerenhovi L, Lindqvist C. Oral sources of septicaemia in patients with malignancies. Oral Oncol 1997; 33 (6): 38997.
  • 25
    Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992; 14 (6): 12017.
  • 26
    Hall G, Heimdahl A, Nord CE. Bacteremia after oral surgery and antibiotic prophylaxis for endocarditis. Clin Infect Dis 1999; 29 (1): 18.
  • 27
    Lucas VS, Beighton D, Roberts GJ, Challacombe SJ. Changes in the oral streptococcal flora of children undergoing allogeneic bone marrow transplantation. J Infect 1997; 35 (2): 13541.
  • 28
    Marron A, Carratala J, Gonzalez-Barca E et al Serious complications of bacteremia caused by viridans streptococci in neutropenic patients with cancer. Clin Infect Dis 2000; 31: 112630.
  • 29
    Dompeling EC, Donnelly JP, Raemaekers JM, De Pauw BE. Pre-emptive administration of corticosteroids prevents the development of ARDS associated with Streptococcus mitis bacteremia following chemotherapy with high-dose cytarabine. Ann Hematol 1994; 69 (2): 6971.
  • 30
    Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25: 24759.
  • 31
    Kern WV, Hay B, Kern P, Marre RE, Arnold RA. Randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis. Antimicrob Agents Chemother 1994; 30: 46572.
  • 32
    Wade JC, Schimpff SC, Newman KA, Wiernik PH. Staphylococcus epidermidis. an increasing cause of infection in patients with granulocytopenia. Ann Intern Med 1982; 97: 5038.
  • 33
    Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, Granena A, Gudiol F. Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis 1996; 15: 2916.
  • 34
    Herwaldt LA, Hollis RJ, Boyken LD, Pfaller MA. Molecular epidemiology of coagulase-negative staphylococci isolated from immunocompromised patients. Infect Control Hosp Epidemiol 1992; 13: 8692.
  • 35
    Kennedy HF, Morrison D, Kaufman M et al Origins of Staphylococcus epidermidis and Streptococcus oralis causing bacteraemia in a bone marrow transplant patient. J Med Microbiol 2000; 49: 36770.